Patents by Inventor Nicholas Timothy Rapson

Nicholas Timothy Rapson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULINS
    Publication number: 20110245470
    Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 16, 2010
    Publication date: October 6, 2011
    Inventors: Jonathan Henry ELLIS, Alexandre EON-DUVAL, Volker GERMASCHEWSKI, Christopher PLUMPTON, Nicholas Timothy RAPSON, Michael Robert WEST
  • Immunoglobulins
    Patent number: 7858753
    Abstract: The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns antibodies that modulate the interaction between both Site II and Site III of OSM and their respective interacting partners. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: December 28, 2010
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Alexandre Eon-Duval, Volker Germaschewski, Christopher Plumpton, Nicholas Timothy Rapson, Michael Robert West
  • Antibodies to CD23, derivatives thereof, and their therapeutic uses
    Patent number: 7008623
    Abstract: The invention relates to antibodies which bind to the CD23 (FC?RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC?RII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol?1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: March 7, 2006
    Assignee: Glaxo Wellcome Inc.
    Inventors: Jean-Yves Marcel Paul Bonnefoy, James Scott Crowe, Jonathan Henry Ellis, Nicholas Timothy Rapson, Jean Shearin
  • Method for culturing Chinese hamster ovary cells
    Patent number: RE41974
    Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: November 30, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Michael John Keen, Nicholas Timothy Rapson